aldicarb sulfoxide: metabolite of aldicarb [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9568700 |
| CHEMBL ID | 1533560 |
| SCHEMBL ID | 3397040 |
| MeSH ID | M0096611 |
| Synonym |
|---|
| 7xx24c9y7x , |
| unii-7xx24c9y7x |
| 2-methyl-2-(methylsulfinyl)propionaldehyde o-(methylcarbamoyl)oxime |
| temik sulfoxide |
| 2-methyl-2-(methylsulfinyl)propanal o-((methylamino)carbonyl)oxime |
| propanal, 2-methyl-2-(methylsulfinyl)-, o-((methylamino)carbonyl)oxime |
| brn 1962013 |
| caswell no. 011aaa |
| propionaldehyde, 2-methyl-2-(methylsulfinyl)-, o-(methylcarbamoyl)oxime |
| NCGC00090719-01 |
| 1646-87-3 |
| aldicarb sulfoxide |
| NCGC00090719-02 |
| (1e)-2-methyl-2-(methylsulfinyl)propanal o-(methylcarbamoyl)oxime |
| SCHEMBL3397040 |
| NCGC00090719-04 |
| NCGC00090719-03 |
| tox21_303449 |
| dtxcid9013161 |
| dtxsid1033161 , |
| cas-1646-87-3 |
| NCGC00257315-01 |
| NCGC00259293-01 |
| tox21_201744 |
| aldicarb-sulfoxide |
| AKOS015894690 |
| aldicarb sulfoxide, e-isomer |
| 5X736K018B |
| propionaldehyde, 2-methyl-2-(methylsulfinyl)-, o-(methylcarbamoyl)oxime, 1e |
| (1e)-2-methyl-1-(([(methylamino)carbonyl]oxy)imino)-2-(methylsulfinyl)propane # |
| propanal, 2-methyl-2-(methylsulfinyl)-, o-[(methylamino)carbonyl]oxime |
| BXPMAGSOWXBZHS-WEVVVXLNSA-N |
| propanal, 2-methyl-2-(methylsulfinyl)-, o-[(methylamino)carbonyl] |
| CHEMBL1533560 |
| [(e)-(2-methyl-2-methylsulfinylpropylidene)amino] n-methylcarbamate |
| J-519548 |
| aldicarb-sulfoxide, pestanal(r), analytical standard |
| J-010158 |
| pesticide2_aldicarb sulfoxide_c7h14n2o3s_propanal, 2-methyl-2-(methylsulfinyl)-, o-[(methylamino)carbonyl]oxime, (1e)- |
| z-isomeraldicarb sulfoxide |
| Q27269178 |
| aldicarb-d3sulfoxide |
| AKOS040750308 |
| 1ST20273 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
| "In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
| ", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 2.8184 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 0.8787 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 40.0852 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 40.0852 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 39.1206 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.1000 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 35.7946 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259394 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 7.6568 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.9991 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 22.1912 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 78.0558 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.1413 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 21.9991 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 19.6067 | 0.0376 | 17.0823 | 61.1927 | AID1259364 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.6082 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||